In addition, serum IgG levels of anti-calreticulin autoantibodies have been found to be significantly higher in bladder cancer patients than in normal controls, leading to the proposal of anti-calreticulin antibodies as a novel biomarker for bladder cancer progression (90). This evidence concerns the gene CALR and urinary bladder carcinoma.